Amgen outlines growth plan, rules out break-up
Biotechnology company Amgen, facing pressure from activist investor Daniel Loeb, Tuesday unveiled plans to implement deeper job cuts, lift shareholder payouts and increase revenues to more than $20 billion in 2015.